Scpharmaceuticals Deferred Long Term Liab vs Net Working Capital Analysis

SCPH Stock

USD 4.75 0.08 1.66%

Scpharmaceuticals financial indicator trend analysis is much more than just breaking down Scpharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Scpharmaceuticals is a good investment. Please check the relationship between Scpharmaceuticals Deferred Long Term Liab and its Net Working Capital accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.

Deferred Long Term Liab vs Net Working Capital

Deferred Long Term Liab vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Scpharmaceuticals Deferred Long Term Liab account and Net Working Capital. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Scpharmaceuticals' Deferred Long Term Liab and Net Working Capital is -0.59. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Scpharmaceuticals, assuming nothing else is changed. The correlation between historical values of Scpharmaceuticals' Deferred Long Term Liab and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Scpharmaceuticals are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Deferred Long Term Liab i.e., Scpharmaceuticals' Deferred Long Term Liab and Net Working Capital go up and down completely randomly.

Correlation Coefficient

-0.59

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Net Working Capital

Most indicators from Scpharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Scpharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.As of now, Scpharmaceuticals' Selling General Administrative is increasing as compared to previous years. The Scpharmaceuticals' current Enterprise Value is estimated to increase to about 246.7 M, while Issuance Of Capital Stock is projected to decrease to under 31.9 M.

	2021	2022	2023	2024 (projected)
Interest Expense	2.6M	3.3M	8.1M	8.5M
Depreciation And Amortization	364K	2.6M	626K	746.3K

Interest Expense Depreciation And Amortization

Scpharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets
Total Assets		0.43	0.72	-0.29	0.49	0.94	0.83	-0.73	-0.77	0.5	0.94	0.87	0.86	0.53	1.0	0.62	0.55	0.1	0.9	0.4	0.43	0.34	0.27	0.61	0.9	1.0
Other Current Liab	0.43		0.46	0.04	0.89	0.36	0.3	0.21	-0.8	0.91	0.23	0.31	0.17	0.1	0.39	0.85	0.69	0.47	0.57	0.86	0.91	0.83	0.55	0.43	0.35	0.43
Total Current Liabilities	0.72	0.46		-0.36	0.51	0.74	0.52	-0.39	-0.86	0.5	0.63	0.57	0.73	0.4	0.69	0.79	0.84	0.05	0.88	0.48	0.51	0.47	0.28	0.59	0.76	0.72
Total Stockholder Equity	-0.29	0.04	-0.36		0.04	-0.2	0.09	0.26	0.28	0.33	-0.25	-0.01	-0.52	-0.57	-0.31	-0.03	-0.46	0.01	-0.38	0.33	0.24	0.46	-0.08	-0.23	-0.33	-0.29
Other Liab	0.49	0.89	0.51	0.04		0.42	0.32	0.22	-0.83	0.85	0.23	0.32	0.35	-0.13	0.45	0.87	0.7	0.43	0.62	0.85	0.95	0.82	0.53	0.49	0.35	0.49
Net Tangible Assets	0.94	0.36	0.74	-0.2	0.42		0.9	-0.71	-0.73	0.44	0.9	0.93	0.84	0.52	0.93	0.59	0.54	-0.18	0.91	0.41	0.4	0.36	0.0	0.65	0.79	0.94
Property Plant And Equipment Net	0.83	0.3	0.52	0.09	0.32	0.9		-0.7	-0.55	0.46	0.84	0.99	0.63	0.31	0.82	0.42	0.31	-0.15	0.72	0.48	0.38	0.41	-0.02	0.71	0.74	0.83
Net Debt	-0.73	0.21	-0.39	0.26	0.22	-0.71	-0.7		0.19	0.07	-0.88	-0.73	-0.65	-0.65	-0.76	-0.02	-0.01	0.19	-0.49	0.18	0.24	0.21	0.1	-0.27	-0.72	-0.73
Retained Earnings	-0.77	-0.8	-0.86	0.28	-0.83	-0.73	-0.55	0.19		-0.76	-0.59	-0.59	-0.68	-0.29	-0.73	-0.94	-0.88	-0.25	-0.91	-0.75	-0.8	-0.69	-0.44	-0.67	-0.7	-0.77
Accounts Payable	0.5	0.91	0.5	0.33	0.85	0.44	0.46	0.07	-0.76		0.34	0.44	0.19	-0.02	0.45	0.88	0.55	0.45	0.55	0.93	0.94	0.95	0.55	0.4	0.43	0.5
Cash	0.94	0.23	0.63	-0.25	0.23	0.9	0.84	-0.88	-0.59	0.34		0.88	0.82	0.62	0.96	0.45	0.34	-0.06	0.76	0.24	0.21	0.19	0.09	0.5	0.85	0.94
Non Current Assets Total	0.87	0.31	0.57	-0.01	0.32	0.93	0.99	-0.73	-0.59	0.44	0.88		0.71	0.39	0.86	0.45	0.36	-0.16	0.77	0.46	0.36	0.37	-0.02	0.72	0.78	0.87
Non Currrent Assets Other	0.86	0.17	0.73	-0.52	0.35	0.84	0.63	-0.65	-0.68	0.19	0.82	0.71		0.43	0.87	0.48	0.5	-0.15	0.81	0.2	0.23	0.11	0.02	0.58	0.73	0.86
Other Assets	0.53	0.1	0.4	-0.57	-0.13	0.52	0.31	-0.65	-0.29	-0.02	0.62	0.39	0.43		0.56	0.18	0.31	-0.19	0.48	-0.19	-0.17	-0.22	-0.09	0.05	0.46	0.53
Cash And Short Term Investments	1.0	0.39	0.69	-0.31	0.45	0.93	0.82	-0.76	-0.73	0.45	0.96	0.86	0.87	0.56		0.58	0.5	0.08	0.88	0.35	0.37	0.29	0.24	0.57	0.88	1.0
Net Receivables	0.62	0.85	0.79	-0.03	0.87	0.59	0.42	-0.02	-0.94	0.88	0.45	0.45	0.48	0.18	0.58		0.8	0.26	0.76	0.83	0.9	0.84	0.44	0.48	0.52	0.62
Common Stock Shares Outstanding	0.55	0.69	0.84	-0.46	0.7	0.54	0.31	-0.01	-0.88	0.55	0.34	0.36	0.5	0.31	0.5	0.8		0.24	0.82	0.58	0.65	0.51	0.43	0.66	0.58	0.55
Non Current Liabilities Total	0.1	0.47	0.05	0.01	0.43	-0.18	-0.15	0.19	-0.25	0.45	-0.06	-0.16	-0.15	-0.19	0.08	0.26	0.24		0.08	0.28	0.37	0.28	0.97	0.04	0.32	0.11
Capital Surpluse	0.9	0.57	0.88	-0.38	0.62	0.91	0.72	-0.49	-0.91	0.55	0.76	0.77	0.81	0.48	0.88	0.76	0.82	0.08		0.52	0.56	0.45	0.28	0.71	0.84	0.9
Inventory	0.4	0.86	0.48	0.33	0.85	0.41	0.48	0.18	-0.75	0.93	0.24	0.46	0.2	-0.19	0.35	0.83	0.58	0.28	0.52		0.96	0.97	0.38	0.6	0.34	0.4
Other Current Assets	0.43	0.91	0.51	0.24	0.95	0.4	0.38	0.24	-0.8	0.94	0.21	0.36	0.23	-0.17	0.37	0.9	0.65	0.37	0.56	0.96		0.95	0.47	0.5	0.32	0.43
Other Stockholder Equity	0.34	0.83	0.47	0.46	0.82	0.36	0.41	0.21	-0.69	0.95	0.19	0.37	0.11	-0.22	0.29	0.84	0.51	0.28	0.45	0.97	0.95		0.38	0.43	0.27	0.34
Total Liab	0.27	0.55	0.28	-0.08	0.53	0.0	-0.02	0.1	-0.44	0.55	0.09	-0.02	0.02	-0.09	0.24	0.44	0.43	0.97	0.28	0.38	0.47	0.38		0.17	0.48	0.27
Property Plant And Equipment Gross	0.61	0.43	0.59	-0.23	0.49	0.65	0.71	-0.27	-0.67	0.4	0.5	0.72	0.58	0.05	0.57	0.48	0.66	0.04	0.71	0.6	0.5	0.43	0.17		0.66	0.61
Preferred Stock Total Equity	0.9	0.35	0.76	-0.33	0.35	0.79	0.74	-0.72	-0.7	0.43	0.85	0.78	0.73	0.46	0.88	0.52	0.58	0.32	0.84	0.34	0.32	0.27	0.48	0.66		0.9
Total Current Assets	1.0	0.43	0.72	-0.29	0.49	0.94	0.83	-0.73	-0.77	0.5	0.94	0.87	0.86	0.53	1.0	0.62	0.55	0.11	0.9	0.4	0.43	0.34	0.27	0.61	0.9

Click cells to compare fundamentals

Scpharmaceuticals Account Relationship Matchups

Scpharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	77.3M	109.0M	79.0M	124.2M	94.5M	90.6M
Other Current Liab	3.7M	4.8M	26K	5.3M	9.0M	9.4M
Total Current Liabilities	5.2M	9.3M	14.8M	7.4M	13.1M	8.3M
Total Stockholder Equity	(129.5M)	(161.7M)	(189.7M)	(226.5M)	37.2M	39.1M
Other Liab	58K	219K	367K	7.5M	8.7M	9.1M
Net Tangible Assets	51.4M	82.2M	63.1M	72.4M	83.3M	54.8M
Property Plant And Equipment Net	1.3M	908K	479K	620K	1.5M	1.0M
Net Debt	(52.5M)	(85.1M)	(56.6M)	(33.7M)	(6.5M)	(6.9M)
Retained Earnings	(129.5M)	(161.7M)	(189.7M)	(226.5M)	(281.3M)	(267.3M)
Accounts Payable	1.1M	1.7M	544K	1.5M	4.0M	4.2M
Cash	72.8M	105.3M	74.3M	71.1M	46.8M	75.7M
Non Current Assets Total	1.6M	1.2M	762K	887K	1.5M	1.2M
Non Currrent Assets Other	148K	132K	283K	267K	82.0K	159.4K
Other Assets	330K	1.1M	283K	267K	1.0	0.95
Cash And Short Term Investments	72.8M	105.3M	75.5M	118.4M	76.0M	85.2M
Net Receivables	655K	479K	310K	2.3M	4.5M	4.7M
Common Stock Shares Outstanding	18.6M	24.6M	27.4M	28.4M	38.5M	22.2M
Liabilities And Stockholders Equity	(103.5M)	(134.8M)	(167.1M)	(174.8M)	94.5M	99.2M
Non Current Liabilities Total	20.7M	17.6M	7.7M	44.3M	44.1M	29.9M
Capital Surpluse	180.8M	243.8M	246.2M	298.9M	343.8M	182.1M
Inventory	1.6M	2.4M	0.0	1.2M	8.8M	9.3M
Other Current Assets	94K	121K	24K	1.4M	3.6M	3.8M
Other Stockholder Equity	598K	(2K)	(4K)	(35K)	318.6M	334.5M
Total Liab	25.9M	26.9M	22.6M	51.8M	57.3M	38.2M
Property Plant And Equipment Gross	1.3M	93K	649K	808K	1.5M	769.8K
Total Current Assets	75.6M	107.8M	78.3M	123.3M	92.9M	89.4M
Accumulated Other Comprehensive Income	(600K)	(102K)	1K	(1K)	32K	(1.1K)
Property Plant Equipment	1.3M	908K	69K	54K	48.6K	46.2K
Non Current Liabilities Other	58K	219K	367K	35K	177K	147.7K
Short Long Term Debt Total	20.3M	20.2M	17.6M	37.4M	40.3M	24.9M
Long Term Debt	18.9M	16.9M	7.4M	36.8M	38.8M	21.2M
Long Term Debt Total	18.9M	16.9M	7.4M	36.8M	42.3M	44.4M
Capital Lease Obligations	1.4M	940K	476K	574K	1.5M	963.3K
Net Invested Capital	70.3M	101.4M	73.6M	109.2M	76.0M	72.5M
Net Working Capital	70.4M	98.5M	63.4M	115.9M	79.8M	71.8M
Short Term Debt	407K	2.9M	10.3M	567K	176K	167.2K

Currently Active Assets on Macroaxis

S	SentinelOne
GOOG	Alphabet Inc Class C
C	Citigroup
GM	General Motors
C	Citigroup

When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:

How To Invest In Scpharmaceuticals

Details

Is Scpharmaceuticals Stock a good investment?

Details

What is Scpharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Complementary Tools for Scpharmaceuticals Stock analysis

When running Scpharmaceuticals' price analysis, check to measure Scpharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scpharmaceuticals is operating at the current time. Most of Scpharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Scpharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scpharmaceuticals' price. Additionally, you may evaluate how the addition of Scpharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	CEOs Directory Screen CEOs from public companies around the world
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm

Is Scpharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.48)

Revenue Per Share

0.454

Quarterly Revenue Growth

1.958

Return On Assets

(0.36)

Return On Equity

(1.15)

The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Scpharmaceuticals Deferred Long Term Liab vs Net Working Capital Analysis

Deferred Long Term Liab vs Net Working Capital

Deferred Long Term Liab vs Net Working Capital Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Net Working Capital

Scpharmaceuticals fundamental ratios Correlations

Scpharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Scpharmaceuticals fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Scpharmaceuticals Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Total Liab	+ 0.97	Non Current Liabilities Total
Other Stockholder Equity	+ 0.97	Inventory

Net Receivables	- 0.94	Retained Earnings
Capital Surpluse	- 0.91	Retained Earnings
Common Stock Shares Outstanding	- 0.88	Retained Earnings
Cash	- 0.88	Net Debt
Retained Earnings	- 0.86	Total Current Liabilities
Retained Earnings	- 0.83	Other Liab